Nicotinamide mononucleotide (NMN) intake increases plasma NMN and insulin levels in healthy subjects
Clinical Nutrition ESPEN · 2023
DOI: 10.1016/j.clnesp.2023.04.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nutrition ESPEN, 2023. Verfasst von Takuya Yamane und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Metabolomics, BYU-Analytica Inc., Suita, Osaka, 565-0871, Japan; Department of Biotechnology, Graduate School of Engineering, Osaka Univ…. Hauptthemen laut MEDLINE: Insulins, Nicotinamide Mononucleotide. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Nicotinamide adenine dinucleotide (NAD+) is a coenzyme of the NAD+-dependent protein deacetylase sirtuin-1 (SIRT1). An increase in NAD+ concentration induces SIRT1 activation that results in various health benefits. Since nicotinamide mononucleotide (NMN) is a precursor of NAD+, NMN ingestion is expected to have multiple health benefits such as alleviation of aging, lifestyle-related and neurodegenerative diseases, through the activation of SIRT1. In this study, we aimed to determine the effects of daily NMN ingestion on plasma levels of NMN and NAD+. METHODS: Healthy volunteers received 250 mg of NMN once a day in the morning (n = 11) for 12 weeks, and the plasma concentrations of NMN and NAD+ were measured monthly. Physiological and laboratory tests were performed within 2 h after lunch (at 2 pm) before and during NMN administration. RESULTS: Oral administration of NMN increased the plasma concentrations of NMN and NAD+, and the postprandial serum insulin levels. The elevation levels of NMN and insulin varied widely among individuals. No adverse symptoms were observed in the participants. CONCLUSIONS: Oral administration of NMN elevates plasma levels of NMN and NAD+, and postprandial serum insulin levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Metabolomics, BYU-Analytica Inc., Suita, Osaka, 565-0871, Japan; Department of Biotechnology, Graduate School of Engineering, Osaka University, Suita, Osaka, 565-0871, Japan. Electronic address: takuya.yama…
- Institute of Metabolomics, BYU-Analytica Inc., Suita, Osaka, 565-0871, Japan; Department of Biotechnology, Graduate School of Engineering, Osaka University, Suita, Osaka, 565-0871, Japan.
- Institute of Metabolomics, BYU-Analytica Inc., Suita, Osaka, 565-0871, Japan; Division of Metabolomics/Mass Spectrometry Center, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu U…
Zitieren
APA
Yamane, T., Imai, M., Bamba, T., & Uchiyama, S. (2023). Nicotinamide mononucleotide (NMN) intake increases plasma NMN and insulin levels in healthy subjects. Clinical Nutrition ESPEN. https://doi.org/10.1016/j.clnesp.2023.04.031
Vancouver
Yamane T, Imai M, Bamba T, Uchiyama S. Nicotinamide mononucleotide (NMN) intake increases plasma NMN and insulin levels in healthy subjects. Clinical Nutrition ESPEN. 2023. doi:10.1016/j.clnesp.2023.04.031
BibTeX
@article{Yamane2023,
author = {Yamane, Takuya and Imai, Momoko and Bamba, Takeshi and Uchiyama, Susumu},
title = {Nicotinamide mononucleotide (NMN) intake increases plasma NMN and insulin levels in healthy subjects},
journal = {Clinical Nutrition ESPEN},
year = {2023},
doi = {10.1016/j.clnesp.2023.04.031}
}
EUVIMED